Initially, the gp100-TCRs have been cloned first into a TCR-negative Jurkat cell line for characterising their reactivity profiles using a series of flow cytometry based co-culture assays, before transduction into primary cells for assessment of tumour-killing potential. This evidence concerns the gene PMEL and neoplasm.